Skip to main content
SpringerLink
Log in
Book cover

Cancer Biomarkers in Body Fluids pp 179–212Cite as

Gastric Cancer Biomarkers in Circulation

  • Chapter
  • First Online:

  • 1243 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–5.

    Article  CAS  PubMed  Google Scholar 

  2. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

    Article  CAS  PubMed  Google Scholar 

  3. Graham DY, Klein PD, Evans Jr DJ, et al. Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet. 1987;1:1174–7.

    Google Scholar 

  4. Marshall BJ, Surveyor I. Carbon-14 urea breath test for the diagnosis of Campylobacter pylori associated gastritis. J Nucl Med. 1988;29:11–6.

    CAS  PubMed  Google Scholar 

  5. Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels—“ABC method”. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:405–14.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kurilovich S, Belkovets A, Reshetnikov O, et al. Stomach-specific Biomarkers (GastroPanel) Can Predict the Development of Gastric Cancer in a Caucasian Population: A Longitudinal Nested Case-Control Study in Siberia. Anticancer Res. 2016;36:247–53.

    CAS  PubMed  Google Scholar 

  7. Sai S, Ichikawa D, Tomita H, et al. Quantification of plasma cell-free DNA in patients with gastric cancer. Anticancer Res. 2007;27:2747–51.

    CAS  PubMed  Google Scholar 

  8. Park JL, Kim HJ, Choi BY, et al. Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. Oncol Lett. 2012;3:921–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Kim K, Shin DG, Park MK, et al. Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection. Ann Surg Treat Res. 2014;86:136–42.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Ichikawa D, Koike H, Ikoma H, et al. Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer. Anticancer Res. 2004;24:2477–81.

    CAS  PubMed  Google Scholar 

  11. Ikoma H, Ichikawa D, Daito I, et al. Clinical application of methylation specific-polymerase chain reaction in serum of patients with gastric cancer. Hepatogastroenterology. 2007;54:946–50.

    CAS  PubMed  Google Scholar 

  12. Lee TL, Leung WK, Chan MW, et al. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res. 2002;8:1761–6.

    CAS  PubMed  Google Scholar 

  13. Kanyama Y, Hibi K, Nakayama H, et al. Detection of p16 promoter hypermethylation in serum of gastric cancer patients. Cancer Sci. 2003;94:418–20.

    Article  CAS  PubMed  Google Scholar 

  14. Koike H, Ichikawa D, Ikoma H, et al. Comparison of methylation-specific polymerase chain reaction (MSP) with reverse transcriptase-polymerase chain reaction (RT-PCR) in peripheral blood of gastric cancer patients. J Surg Oncol. 2004;87:182–6.

    Article  CAS  PubMed  Google Scholar 

  15. Koike H, Ichikawa D, Ikoma H, et al. Comparison of serum aberrant methylation and conventional tumor markers in gastric cancer patients. Hepatogastroenterology. 2005;52:1293–6.

    CAS  PubMed  Google Scholar 

  16. Raja UM, Gopal G, Rajkumar T. Intragenic DNA methylation concomitant with repression of ATP4B and ATP4A gene expression in gastric cancer is a potential serum biomarker. Asian Pac J Cancer Prev. 2012;13:5563–8.

    Article  PubMed  Google Scholar 

  17. Ikoma H, Ichikawa D, Koike H, et al. Correlation between serum DNA methylation and prognosis in gastric cancer patients. Anticancer Res. 2006;26:2313–6.

    CAS  PubMed  Google Scholar 

  18. Ling ZQ, Lv P, Lu XX, et al. Circulating Methylated DNA Indicates Poor Prognosis for Gastric Cancer. PLoS One. 2013;8:e67195.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Sakakura C, Hamada T, Miyagawa K, et al. Quantitative analysis of tumor-derived methylated RUNX3 sequences in the serum of gastric cancer patients. Anticancer Res. 2009;29:2619–25.

    CAS  PubMed  Google Scholar 

  20. Sapari NS, Loh M, Vaithilingam A, Soong R. Clinical potential of DNA methylation in gastric cancer: a meta-analysis. PLoS One. 2012;7:e36275.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Schurr PG, Oikonomou D, Kaifi JT, et al. Clinical value of loss of heterozygosity in serum microsatellite DNA of patients with gastrointestinal stromal tumors. J Clin Gastroenterol. 2009;43:27–35.

    Article  CAS  PubMed  Google Scholar 

  22. Rawnaq T, Schwarzenbach H, Schurr PG, et al. Monitoring of loss of heterozygosity in serum microsatellite DNA among patients with gastrointestinal stromal tumors indicates tumor recurrence. J Surg Res. 2011;169:31–5.

    Article  CAS  PubMed  Google Scholar 

  23. Maeta M, Saito H, Oka S, et al. Mutated p53 in tumors, mutant p53 and p53-specific antibodies in the circulation in patients with gastric cancer. J Exp Clin Cancer Res. 2000;19:489–95.

    CAS  PubMed  Google Scholar 

  24. Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 2010;102:1174–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Zhou H, Guo JM, Lou YR, et al. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J Mol Med (Berl). 2010;88:709–17.

    Article  CAS  Google Scholar 

  26. Zheng Y, Cui L, Sun W, et al. MicroRNA-21 is a new marker of circulating tumor cells in gastric cancer patients. Cancer Biomark. 2011;10:71–7.

    CAS  PubMed  Google Scholar 

  27. Liu R, Zhang C, Hu Z, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 2011;47:784–91.

    Article  CAS  PubMed  Google Scholar 

  28. Liu H, Zhu L, Liu B, et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 2012;316:196–203.

    Article  CAS  PubMed  Google Scholar 

  29. Konishi H, Ichikawa D, Komatsu S, et al. Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. Br J Cancer. 2012;106:740–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Gorur A, Balci Fidanci S, Dogruer Unal N, et al. Determination of plasma microRNA for early detection of gastric cancer. Mol Biol Rep. 2013;40:2091–6.

    Article  CAS  PubMed  Google Scholar 

  31. Song JH, Meltzer SJ. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology. 2012;143:35–47. e32

    Article  CAS  PubMed  Google Scholar 

  32. Li C, Li JF, Cai Q, et al. MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer. J Surg Oncol. 2013;108:89–92.

    Article  CAS  PubMed  Google Scholar 

  33. Zhang WH, Gui JH, Wang CZ, et al. The identification of miR-375 as a potential biomarker in distal gastric adenocarcinoma. Oncol Res. 2012;20:139–47.

    Article  CAS  PubMed  Google Scholar 

  34. Zhu X, Lv M, Wang H, Guan W. Identification of circulating microRNAs as novel potential biomarkers for gastric cancer detection: a systematic review and meta-analysis. Dig Dis Sci. 2014;59:911–9.

    Article  CAS  PubMed  Google Scholar 

  35. Zhou X, Ji G, Chen H, et al. Clinical role of circulating miR-223 as a novel biomarker in early diagnosis of cancer patients. Int J Clin Exp Med. 2015;8:16890–8.

    PubMed  PubMed Central  Google Scholar 

  36. Tsai KW, Liao YL, Wu CW, et al. Aberrant expression of miR-196a in gastric cancers and correlation with recurrence. Genes Chromosomes Cancer. 2012;51:394–401.

    Article  CAS  PubMed  Google Scholar 

  37. Ma GJ, Gu RM, Zhu M, et al. Plasma post-operative miR-21 expression in the prognosis of gastric cancers. Asian Pac J Cancer Prev. 2013;14:7551–4.

    Article  PubMed  Google Scholar 

  38. Kim SY, Jeon TY, Choi CI, et al. Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. J Mol Diagn. 2013;15:661–9.

    Article  PubMed  CAS  Google Scholar 

  39. Komatsu S, Ichikawa D, Tsujiura M, et al. Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. Anticancer Res. 2013;33:271–6.

    PubMed  Google Scholar 

  40. Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, et al. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med. 2012;10:186.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Wang M, Gu H, Wang S, et al. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. Mol Med Rep. 2012;5:1514–20.

    CAS  PubMed  Google Scholar 

  42. Li BS, Zhao YL, Guo G, et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One. 2012;7:e41629.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Zhu C, Ren C, Han J, et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer. 2014;110:2291–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Li C, Li JF, Cai Q, et al. miRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer. Ann Surg Oncol. 2013;20(Suppl 3):S397–405.

    Article  PubMed  Google Scholar 

  45. Rotkrua P, Shimada S, Mogushi K, et al. Circulating microRNAs as biomarkers for early detection of diffuse-type gastric cancer using a mouse model. Br J Cancer. 2013;108:932–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Pang Q, Ge J, Shao Y, et al. Increased expression of long intergenic non-coding RNA LINC00152 in gastric cancer and its clinical significance. Tumour Biol. 2014;35:5441–7.

    Article  CAS  PubMed  Google Scholar 

  47. Arita T, Ichikawa D, Konishi H, et al. Circulating long non-coding RNAs in plasma of patients with gastric cancer. Anticancer Res. 2013;33:3185–93.

    CAS  PubMed  Google Scholar 

  48. Liu Z, Shao Y, Tan L, et al. Clinical significance of the low expression of FER1L4 in gastric cancer patients. Tumour Biol. 2014;35:9613–7.

    Article  CAS  PubMed  Google Scholar 

  49. Dong L, Qi P, Xu MD, et al. Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls. Int J Cancer. 2015;137:1128–35.

    Article  CAS  PubMed  Google Scholar 

  50. Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17:26–33.

    Article  CAS  PubMed  Google Scholar 

  51. Deng K, Yang L, Hu B, et al. The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14651 patients. PLoS One. 2015;10:e0124151.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Song YX, Huang XZ, Gao P, et al. Clinicopathologic and Prognostic Value of Serum Carbohydrate Antigen 19-9 in Gastric Cancer: A Meta-Analysis. Dis Markers. 2015;2015:549843.

    PubMed  PubMed Central  Google Scholar 

  53. Zayakin P, Ancans G, Silina K, et al. Tumor-associated autoantibody signature for the early detection of gastric cancer. Int J Cancer. 2013;132:137–47.

    Article  CAS  PubMed  Google Scholar 

  54. Zhang JY, Casiano CA, Peng XX, et al. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev. 2003;12:136–43.

    CAS  PubMed  Google Scholar 

  55. Koziol JA, Zhang JY, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res. 2003;9:5120–6.

    CAS  PubMed  Google Scholar 

  56. Zhou SL, Ku JW, Fan ZM, et al. Detection of autoantibodies to a panel of tumor-associated antigens for the diagnosis values of gastric cardia adenocarcinoma. Dis Esophagus. 2015;28:371–9.

    Article  CAS  PubMed  Google Scholar 

  57. Xu QW, Zhao W, Wang Y, et al. An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer. Cancer Res. 2012;72:6351–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Looi K, Megliorino R, Shi FD, et al. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep. 2006;16:1105–10.

    CAS  PubMed  Google Scholar 

  59. Zhang JY, Chan EK, Peng XX, et al. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol. 2001;100:149–56.

    Article  CAS  PubMed  Google Scholar 

  60. Werner S, Chen H, Tao S, Brenner H. Systematic review: serum autoantibodies in the early detection of gastric cancer. Int J Cancer. 2015;136:2243–52.

    Article  CAS  PubMed  Google Scholar 

  61. Ebert MP, Meuer J, Wiemer JC, et al. Identification of gastric cancer patients by serum protein profiling. J Proteome Res. 2004;3:1261–6.

    Article  CAS  PubMed  Google Scholar 

  62. Liang Y, Fang M, Li J, et al. Serum proteomic patterns for gastric lesions as revealed by SELDI mass spectrometry. Exp Mol Pathol. 2006;81:176–80.

    Article  CAS  PubMed  Google Scholar 

  63. Lu HB, Zhao C, Ma YY. The early gastric clinical significance of serum protein fingerprint diagnostic. Progress Med Biomed. 2006;11:120–6.

    Google Scholar 

  64. Poon TC, Sung JJ, Chow SM, et al. Diagnosis of gastric cancer by serum proteomic fingerprinting. Gastroenterology. 2006;130:1858–64.

    Article  CAS  PubMed  Google Scholar 

  65. Lim JY, Cho JY, Paik YH, et al. Diagnostic application of serum proteomic patterns in gastric cancer patients by ProteinChip surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Int J Biol Markers. 2007;22:281–6.

    CAS  PubMed  Google Scholar 

  66. Su Y, Shen J, Qian H, et al. Diagnosis of gastric cancer using decision tree classification of mass spectral data. Cancer Sci. 2007;98:37–43.

    Article  CAS  PubMed  Google Scholar 

  67. Wang YS, Shen J, Yu JK, et al. [Protein profiles of serum in gastric cancer at a high-risk area by SELDI-TOF mass spectrometry]. Zhonghua Yu Fang Yi Xue Za Zhi. 2008;42:677–80.

    Google Scholar 

  68. Liu C, Xu L, Han HB. Preliminary study of serum protein fingerprint screening gastric cancer serum markers. Bases Clin Med. 2009;16:237–40.

    Google Scholar 

  69. Xue WC, Feng K, Meng DY. Serum protein fingerprint for the early diagnosis of gastric cancer. J Pract Diagn Ther. 2009;18:153–6.

    Google Scholar 

  70. Lu HB, Zhou JH, Ma YY, et al. Five serum proteins identified using SELDI-TOF-MS as potential biomarkers of gastric cancer. Jpn J Clin Oncol. 2010;40:336–42.

    Article  PubMed  Google Scholar 

  71. Liu W, Gao X, Cai Q. Identification of novel serum biomarkers for gastric cancer by magnetic bead. Front Biosci (Elite Ed). 2010;2:961–71.

    Article  Google Scholar 

  72. Wang WJ, Liu C, Liu P. SELDI-TOF-MS technology screening gastric cancer serum markers. Environ Occup Med. 2007;24:143–6.

    Google Scholar 

  73. Ebert MP, Niemeyer D, Deininger SO, et al. Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. J Proteome Res. 2006;5:2152–8.

    Article  CAS  PubMed  Google Scholar 

  74. Kobayashi Y, Niwa Y, Tajika M, et al. Serum tumor antigen REG4 as a useful diagnostic biomarker in gastric cancer. Hepatogastroenterology. 2010;57:1631–4.

    CAS  PubMed  Google Scholar 

  75. Zheng ZG, Xu SH, Xu Q, et al. [Use of serum protein profiling for early diagnosis of gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. 2010;13:770–3.

    Google Scholar 

  76. Umemura H, Togawa A, Sogawa K, et al. Identification of a high molecular weight kininogen fragment as a marker for early gastric cancer by serum proteome analysis. J Gastroenterol. 2011;46:577–85.

    Article  CAS  PubMed  Google Scholar 

  77. Tseng CW, Yang JC, Chen CN, et al. Identification of 14-3-3beta in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker. Proteomics. 2011;11:2423–39.

    Article  CAS  PubMed  Google Scholar 

  78. Cohen M, Yossef R, Erez T, et al. Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays. PLoS One. 2011;6:e14540.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Ahn HS, Shin YS, Park PJ, et al. Serum biomarker panels for the diagnosis of gastric adenocarcinoma. Br J Cancer. 2012;106:733–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Liu W, Liu B, Cai Q, et al. Proteomic identification of serum biomarkers for gastric cancer using multi-dimensional liquid chromatography and 2D differential gel electrophoresis. Clin Chim Acta. 2012;413:1098–106.

    Article  CAS  PubMed  Google Scholar 

  81. Yang J, Xiong X, Wang X, et al. Identification of peptide regions of SERPINA1 and ENOSF1 and their protein expression as potential serum biomarkers for gastric cancer. Tumour Biol. 2015;36:5109–18.

    Article  CAS  PubMed  Google Scholar 

  82. Loei H, Tan HT, Lim TK, et al. Mining the gastric cancer secretome: identification of GRN as a potential diagnostic marker for early gastric cancer. J Proteome Res. 2012;11:1759–72.

    Article  CAS  PubMed  Google Scholar 

  83. Gomceli I, Bostanci EB, Ozer I, et al. A novel screening biomarker in gastric cancer: serum Dickkopf-1. Hepatogastroenterology. 2012;59:1661–4.

    PubMed  Google Scholar 

  84. Fan NJ, Li K, Liu QY, et al. Identification of tubulin beta chain, thymosin beta-4-like protein 3, and cytochrome b-c(1) complex subunit 1 as serological diagnostic biomarkers of gastric cancer. Clin Biochem. 2013;46:1578–84.

    Article  CAS  PubMed  Google Scholar 

  85. Gomes C, Almeida A, Ferreira JA, et al. Glycoproteomic analysis of serum from patients with gastric precancerous lesions. J Proteome Res. 2013;12:1454–66.

    Article  CAS  PubMed  Google Scholar 

  86. Ren J, Chen Z, Juan SJ, et al. Detection of circulating gastric carcinoma-associated antigen MG7-Ag in human sera using an established single determinant immuno-polymerase chain reaction technique. Cancer. 2000;88:280–5.

    Article  CAS  PubMed  Google Scholar 

  87. Fang X, Tie J, Xie Y, et al. Detection of gastric carcinoma-associated antigen MG7-Ag in human sera using surface plasmon resonance sensor. Cancer Epidemiol. 2010;34:648–51.

    Article  CAS  PubMed  Google Scholar 

  88. Zeng Z, Fu S, Hu P, et al. The diagnostic value of monoclonal gastric cancer 7 antigen: a systematic review with meta-analysis. Clin Exp Med. 2014;14:337–43.

    Article  CAS  PubMed  Google Scholar 

  89. Helgason HH, Engwegen JY, Zapatka M, et al. Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer. Oncol Lett. 2010;1:327–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Chan DC, Chen CJ, Chu HC, et al. Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol. 2007;14:84–93.

    Article  PubMed  Google Scholar 

  91. Qiu FM, Yu JK, Chen YD, et al. Mining novel biomarkers for prognosis of gastric cancer with serum proteomics. J Exp Clin Cancer Res. 2009;28:126.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  92. Tao HQ, He XJ, Ma YY, et al. Evaluation of REG4 for early diagnosis and prognosis of gastric cancer. Hum Pathol. 2011;42:1401–9.

    Article  CAS  PubMed  Google Scholar 

  93. Yasuda H, Toiyama Y, Ohi M, et al. Serum soluble vascular adhesion protein-1 is a valuable prognostic marker in gastric cancer. J Surg Oncol. 2011;103:695–9.

    Article  CAS  PubMed  Google Scholar 

  94. Yu L, Aa J, Xu J, et al. Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011;26:1290–7.

    Article  CAS  PubMed  Google Scholar 

  95. Song H, Peng JS, Dong-Sheng Y, et al. Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012;45:78–85.

    Article  CAS  PubMed  Google Scholar 

  96. Ikeda A, Nishiumi S, Shinohara M, et al. Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012;26:548–58.

    Article  CAS  PubMed  Google Scholar 

  97. Miyagi Y, Higashiyama M, Gochi A, et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One. 2011;6:e24143.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Tang L, Zhao S, Liu W, et al. Diagnostic accuracy of circulating tumor cells detection in gastric cancer: systematic review and meta-analysis. BMC Cancer. 2013;13:314.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Uenosono Y, Arigami T, Kozono T, et al. Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer. Cancer. 2013;119:3984–91.

    Article  PubMed  Google Scholar 

  100. Ito H, Inoue H, Sando N, et al. Prognostic impact of detecting viable circulating tumour cells in gastric cancer patients using a telomerase-specific viral agent: a prospective study. BMC Cancer. 2012;12:346.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Matsusaka S, Chin K, Ogura M, et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer Sci. 2010;101:1067–71.

    Article  CAS  PubMed  Google Scholar 

  102. Hiraiwa K, Takeuchi H, Hasegawa H, et al. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol. 2008;15:3092–100.

    Article  PubMed  Google Scholar 

  103. Cao W, Yang W, Li H, et al. Using detection of survivin-expressing circulating tumor cells in peripheral blood to predict tumor recurrence following curative resection of gastric cancer. J Surg Oncol. 2011;103:110–5.

    Article  PubMed  Google Scholar 

  104. Bertazza L, Mocellin S, Marchet A, et al. Survivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival. J Transl Med. 2009;7:111.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  105. Yie SM, Lou B, Ye SR, et al. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann Surg Oncol. 2008;15:3073–82.

    Article  PubMed  Google Scholar 

  106. Yeh KH, Chen YC, Yeh SH, et al. Detection of circulating cancer cells by nested reverse transcription-polymerase chain reaction of cytokeratin-19 (K19)--possible clinical significance in advanced gastric cancer. Anticancer Res. 1998;18:1283–6.

    CAS  PubMed  Google Scholar 

  107. Marrelli D, Pinto E, De Stefano A, et al. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg. 2001;181:16–9.

    Article  CAS  PubMed  Google Scholar 

  108. Illert B, Fein M, Otto C, et al. Disseminated tumor cells in the blood of patients with gastric cancer are an independent predictive marker of poor prognosis. Scand J Gastroenterol. 2005;40:843–9.

    Article  PubMed  Google Scholar 

  109. Kolodziejczyk P, Pituch-Noworolska A, Drabik G, et al. The effects of preoperative chemotherapy on isolated tumour cells in the blood and bone marrow of gastric cancer patients. Br J Cancer. 2007;97:589–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Koga T, Tokunaga E, Sumiyoshi Y, et al. Detection of circulating gastric cancer cells in peripheral blood using real time quantitative RT-PCR. Hepatogastroenterology. 2008;55:1131–5.

    CAS  PubMed  Google Scholar 

  111. Wu CH, Lin SR, Hsieh JS, et al. Molecular detection of disseminated tumor cells in the peripheral blood of patients with gastric cancer: evaluation of their prognostic significance. Dis Markers. 2006;22:103–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Ikeguchi M, Kaibara N. Detection of circulating cancer cells after a gastrectomy for gastric cancer. Surg Today. 2005;35:436–41.

    Article  CAS  PubMed  Google Scholar 

  113. Mimori K, Fukagawa T, Kosaka Y, et al. A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bone marrow in gastric cancer cases. Ann Surg Oncol. 2008;15:2934–42.

    Article  PubMed  Google Scholar 

  114. Arigami T, Uenosono Y, Hirata M, et al. B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells. Cancer Sci. 2011;102:1019–24.

    Article  CAS  PubMed  Google Scholar 

  115. Baran J, Baj-Krzyworzeka M, Weglarczyk K, et al. Circulating tumour-derived microvesicles in plasma of gastric cancer patients. Cancer Immunol Immunother. 2010;59:841–50.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Sciences Division Northern Ontario School of Medicine West Campus, Lakehead University, Thunder Bay, Ontario, Canada

    Gabriel D. Dakubo

Authors
  1. Gabriel D. Dakubo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Dakubo, G.D. (2017). Gastric Cancer Biomarkers in Circulation. In: Cancer Biomarkers in Body Fluids. Springer, Cham. https://doi.org/10.1007/978-3-319-48360-3_6

Download citation

Publish with us

Policies and ethics

Search

Navigation